Neo-Imuntech announced on the 8th that it has submitted a stock report for listing on the KOSDAQ market to the Financial Services Commission.
Neoimmuntech is a next-generation immunotherapy development company headquartered in the United States. It is developing anticancer treatments and infectious diseases treatments.
The company’s representative new drug candidate (pipeline) is’NT-I7 (efineptakin alfa)’, an immune anticancer drug. It is a T-cell amplifying agent that combines the interleukin-7 molecule stabilized with patented technology and the protein sustained platform technology’hyFc’. Through clinical studies, the company has demonstrated that NT-17 amplifies and activates T cells in cancer patients and patients with lymphopenia.
Neo-Imuntech is promoting the listing of special technology cases. It is a strategy to further strengthen pipeline development and focus on global clinical and commercialization through listing on the KOSDAQ. The public offering funds are planned to be used for research and development, facilities and operation funds.
Through this, the goal is to develop innovative treatments for immune and infectious diseases, and to leap forward as a leading company in the market for immune anticancer drugs.
Yang Se-hwan, CEO of Neoimmuntech, said, “We decided that now is the right time to list for strategic investments in the clinical development and commercialization of NT-I7.” We will strive to maximize corporate value and competitiveness.”
The company is aiming to go public in the middle of next month. The total number of publicly offered shares is 1.5 million DR (deposited securities). It is 100% new stock recruitment.
The bid price is 5400~6400 won. It is expected to raise up to about 96 billion won. On the 1st and 2nd of next month, the demand forecast is carried out to determine the final offering price on the 4th. Subsequently, general subscriptions are received on the 5th and 8th. The organizer is Hana Financial Investment and Mirae Asset Daewoo(10,150 +1.50%)All.
Reporter Park In-hyuk [email protected]
–
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
–
